换一批去纤苷防治造血干细胞移植后肝静脉闭塞病的研究进展
Research progress of defibrotide in the treatment and prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation
摘要肝静脉闭塞病(HVOD)是造血干细胞移植(HSCT)后的严重并发症之一,重度HVOD患者的死亡率可高达100％.去纤苷是一种具有抗血栓及促进纤溶作用的单链寡核苷酸混合物.近年来,多个临床研究结果说明去纤苷是预防和治疗HSCT后HVOD安全有效的药物.文章就去纤苷的作用机制及其在HSCT后HVOD的治疗及预防中的应用进行总结.
更多相关知识
abstractsHepatic veno-occlusive disease (HVOD) is a serious complication of hematopoietic stem cell transplantation.The mortality rate of severe HVOD (sHVOD) approaches 100 ％.Defibrotide (DF) is a polydisperse mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic properties.Numerous clinical trials have demonstrated its effectiveness and safety in the prevention and treatment of HVOD.This review focuses on the possible mechanisms of action of DF and its use in the prevention and treatment of HVOD.
More相关知识
关键词
造血干细胞移植去纤苷肝静脉闭塞病Hematopoietic stem cell transplantationDefibrotideHepatic veno-occlusive disease
医学主题词
造血干细胞移植(Hematopoietic Stem Cell Transplantation)肝静脉(Hepatic Veins)研究(Research)死亡率(Mortality)血栓形成(Thrombosis)
栏目名称
DOI
10.3760/cma.j.issn.1009-9921.2013.07.003
发布时间
2013-09-03（万方平台首次上网日期，不代表论文的发表时间）
基金项目
- 浏览188
- 被引2
- 下载178
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
